Paradoxical effect of cytosine arabinoside on mouse leukemia cell line L1210 cells. 2005

Tohru Nakayama, and Shinobu Sakamoto, and Shuji Sassa, and Satoe Suzuki, and Hideki Kudo, and Hiroshi Nagasawa
Nursing Science, School of Allied Health Sciences, Faculty of Medicine, Tokyo Medical and Dental University, Japan.

We investigated the effects of 1-beta-D-arabinofuranosylcytosine (ara-C) on the growth of murine leukemic L1210 cells, which were cultured with high (2.0 x 10(3) ng/ml), middle (100 ng/ml) and low doses (5.0 ng/ml) of ara-C. In the analysis by flow cytometry, high dose ara-C arrested the cell cycle in the G0/G1-phase. Middle and low doses ara-C induced a block in the S-phase, that was not completely blocked by the low dose. Analysis of DNA fragmentation revealed that ara-C dose-dependently induced apoptosis, which was only slightly induced by the low dose. We measured activities of cellular thymidylate synthase (TS) and thymidine kinase (TK) after 24-h culture. Low and middle doses, but not high dose ara-C markedly enhanced TS activity to 2.9- in low and 5.3-fold in middle doses ara-C, and TK activity to 1.3- in low and 2.2-fold in middle doses, respectively, compared with those of the control. The cells accumulated in the S-phase by 48-h culture with low dose ara-C and markedly proliferated compared to that of the control in ara-C-free medium. These results indicate that non-high dose ara-C enhances DNA-synthesizing enzyme activities in L1210 cells, and withdrawal of the non-high dose ara-C results in paradoxical cell proliferation. Thus, daily intramuscular injections with an insufficient dose of ara-C may induce cells into S-phase, resulting in the proliferation of leukemic cells.

UI MeSH Term Description Entries
D007939 Leukemia L1210 An experimental LYMPHOCYTIC LEUKEMIA of mice. Leukemia L 1210,L 1210, Leukemia,L1210, Leukemia
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000964 Antimetabolites, Antineoplastic Antimetabolites that are useful in cancer chemotherapy. Antineoplastic Antimetabolites
D013937 Thymidine Kinase An enzyme that catalyzes the conversion of ATP and thymidine to ADP and thymidine 5'-phosphate. Deoxyuridine can also act as an acceptor and dGTP as a donor. (From Enzyme Nomenclature, 1992) EC 2.7.1.21. Deoxythymidine Kinase,Deoxypyrimidine Kinase,Kinase, Deoxypyrimidine,Kinase, Deoxythymidine,Kinase, Thymidine
D013940 Thymidylate Synthase An enzyme of the transferase class that catalyzes the reaction 5,10-methylenetetrahydrofolate and dUMP to dihydrofolate and dTMP in the synthesis of thymidine triphosphate. (From Dorland, 27th ed) EC 2.1.1.45. Thymidylate Synthetase,Synthase, Thymidylate,Synthetase, Thymidylate
D016196 S Phase Phase of the CELL CYCLE following G1 and preceding G2 when the entire DNA content of the nucleus is replicated. It is achieved by bidirectional replication at multiple sites along each chromosome. S Period,Period, S,Periods, S,Phase, S,Phases, S,S Periods,S Phases
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis

Related Publications

Tohru Nakayama, and Shinobu Sakamoto, and Shuji Sassa, and Satoe Suzuki, and Hideki Kudo, and Hiroshi Nagasawa
November 1972, Cancer research,
Tohru Nakayama, and Shinobu Sakamoto, and Shuji Sassa, and Satoe Suzuki, and Hideki Kudo, and Hiroshi Nagasawa
September 1996, The international journal of biochemistry & cell biology,
Tohru Nakayama, and Shinobu Sakamoto, and Shuji Sassa, and Satoe Suzuki, and Hideki Kudo, and Hiroshi Nagasawa
April 1978, Cancer treatment reports,
Tohru Nakayama, and Shinobu Sakamoto, and Shuji Sassa, and Satoe Suzuki, and Hideki Kudo, and Hiroshi Nagasawa
July 1974, European journal of cancer,
Tohru Nakayama, and Shinobu Sakamoto, and Shuji Sassa, and Satoe Suzuki, and Hideki Kudo, and Hiroshi Nagasawa
January 1982, Experimental pathology,
Tohru Nakayama, and Shinobu Sakamoto, and Shuji Sassa, and Satoe Suzuki, and Hideki Kudo, and Hiroshi Nagasawa
September 1968, Biochimica et biophysica acta,
Tohru Nakayama, and Shinobu Sakamoto, and Shuji Sassa, and Satoe Suzuki, and Hideki Kudo, and Hiroshi Nagasawa
November 1989, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
Tohru Nakayama, and Shinobu Sakamoto, and Shuji Sassa, and Satoe Suzuki, and Hideki Kudo, and Hiroshi Nagasawa
January 1978, Journal of surgical oncology,
Tohru Nakayama, and Shinobu Sakamoto, and Shuji Sassa, and Satoe Suzuki, and Hideki Kudo, and Hiroshi Nagasawa
September 1975, European journal of cancer,
Tohru Nakayama, and Shinobu Sakamoto, and Shuji Sassa, and Satoe Suzuki, and Hideki Kudo, and Hiroshi Nagasawa
August 2013, Human gene therapy,
Copied contents to your clipboard!